Pfizer Q3 earnings top forecasts as revenue reaches $16.58B
Key points
- Pfizer reported third-quarter 2026 adjusted earnings of $0.87 per share, exceeding analysts' consensus estimate of approximately $0.73, while revenue reached $16.58 billion.
- GAAP net income declined 8% to $3.24 billion and reported diluted earnings fell to $0.56 per share, despite improved sales from newer pharmaceutical products.
- Pfizer raised its full-year revenue forecast to $62 billion–$64 billion and adjusted earnings guidance to $2.95–$3.05 per share, citing commercial performance and operational discipline.
Pfizer (NYSE:PFE) reported third-quarter 2026 revenue of $16.58 billion, exceeding Wall Street estimates, while adjusted earnings of $0.87 per share surpassed the approximately $0.73 analyst consensus.
Revenue declined slightly from $16.65 billion a year earlier, while GAAP net income fell 8% to $3.24 billion and diluted earnings decreased to $0.56 from $0.62.
Adjusted net income increased 1% to $4.99 billion, while adjusted diluted EPS remained unchanged at $0.87 and revenue from launched and acquired products grew 32% on an operational basis.
Pfizer raised its full-year revenue forecast to $62 billion–$64 billion and adjusted earnings guidance to $2.95–$3.05 per share, reflecting stronger year-to-date performance and confidence in its business.
Excluding COVID-19 products Comirnaty and Paxlovid, quarterly revenue increased 7% operationally, supported by the company's newer medicines and acquired products across its biopharmaceutical portfolio.
The New York-based drugmaker continues investing in oncology, immunology, vaccines and obesity treatments, while advancing its late-stage development pipeline and implementing cost improvement initiatives.
